Inventor · disambiguated record
Aline Van Pel
Also filed as: VAN PEL ALINE
19 granted patents·573 citations·filing 1991–2009
95Inventor score
Top patents by PatentIndex Score
19 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0290US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 0379US6669946B2Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2001·Granted Dec 30, 2003·5 cites·1 claims
- 0479US5487974AMethod for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cellsLUDWIG INST CANCER RES·Filed 1993·Granted Jan 30, 1996·59 cites·6 claims
- 0575US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 0673US5747271AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1996·Granted May 5, 1998·39 cites·2 claims
- 0769US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 0869US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
- 0969US5744316AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Apr 28, 1998·28 cites·10 claims
- 1066US5854203ATumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Dec 29, 1998·25 cites·2 claims
- 1166US5530096AIsolated, tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jun 25, 1996·22 cites·1 claims
- 1262US7785881B2MAGE-C2 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2008·Granted Aug 31, 2010·0 cites·4 claims
- 1357US5837476AMethods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1998·Granted Nov 17, 1998·19 cites·2 claims
- 1456US8519109B2Tumour rejection antigensHUANG LAN-QING·Filed 2009·Granted Aug 27, 2013·0 cites·12 claims
- 1541US5843688AIsolated tyrosinase derived peptides and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Dec 1, 1998·2 cites·3 claims
- 1640US7547439B1Tumor rejection antigensLUDWIG INST CANCER RES·Filed 1999·Granted Jun 16, 2009·5 cites·12 claims
- 1732US7923534B1Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1997·Granted Apr 12, 2011·0 cites·3 claims
- 1831USRE40089ENucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1996·Granted Feb 19, 2008·0 cites·25 claims
- 1929US6284476B1Method of identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1995·Granted Sep 4, 2001·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Aline Van Pel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →